Drug Profile
Research programme: filovirus therapeutics - GNL/Profectus/Arbutus/Vanderbilt
Latest Information Update: 28 Apr 2018
Price :
$50
*
At a glance
- Originator Galveston National Laboratory; Profectus Biosciences; Tekmira Pharmaceuticals Corporation; Vanderbilt University
- Developer Arbutus Biopharma; Galveston National Laboratory; Profectus Biosciences; Vanderbilt University
- Class Monoclonal antibodies; Small interfering RNA; Viral vaccines
- Mechanism of Action Immunomodulators; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Ebola virus infections; Marburg virus disease
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for research development in Ebola-virus-infections in USA (Parenteral)
- 28 Apr 2018 No recent reports of development identified for research development in Marburg virus disease in USA (Parenteral)
- 04 Mar 2014 Early research in Ebola and Marburg virus infections in USA (Parenteral)